Adam Rowe Reflects: A Mother’s Voice

05/08/2015

A mother's voice is the first thing we hear from the time we exit the womb. And its the voice we continue to hear throughout our lives. We model our mother's voice when we first learn to talk. The same voice guides us as we begin to walk. It warns you of potential harm and radiates warmth when you need consolation.

Alzheimer’s Drug Discovery Foundation Connoisseur’s Dinner Raises $2.8 Million

05/04/2015

On Monday, April 27, 2015, American theatre director, choreographer, film director, and performer Susan Stroman hosted the ADDF's Ninth Annual Connoisseur’s Dinner. More than $2.8 million was raised to support Alzheimer's drug discovery and development.

Diane Rehm Hosts 2015 Great Ladies Luncheon & Fashion Show

04/17/2015

On Wednesday, April 15, 2015, renowned journalist and NPR host Diane Rehm welcomed guests to the ADDF's Fifth Annual Great Ladies Luncheon & Fashion Show in Washington, DC. Rehm, who has long used her public platform to raise awareness for Alzheimer’s disease, spoke eloquently about the need to increase support for drug discovery for Alzheimer's.

Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant

04/09/2015

Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the ADDF awarded it a $325,000 grant to support the development of Asceneuron’s tau modulators.

GliaCure Receives $1 Million Grant for Alzheimer’s Clinical Trial

03/17/2015

The ADDF announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109.

Alzheimer’s Drug Discovery Foundation an Official Charity Partner of 2015 TCS New York City Marathon

03/03/2015

The ADDF is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon.

ADDF Teams Up with Pfizer CTI to Support Discovery of Drugs for Alzheimer’s Disease

02/11/2015

The ADDF and Pfizer’s Centers for Therapeutic Innovation (CTI) announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias.

New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial

01/28/2015

The ADDF announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).

New Funding for Italian Biotechnology Company Exploring Novel Drugs for Alzheimer’s Disease

12/18/2014

The ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer’s disease by targeting inflammation. This grant follows two previous awards by ADDF to Axxam in 2011 and 2013. The award will continue to fund a drug discovery project to identify compounds that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain.

Erectile Dysfunction Drug to Be Tested as Dementia Treatment

12/11/2014

Today, the ADDF and the Alzheimer’s Society UK announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership.